Xilio Therapeutics announces collaboration with AbbVie for tumor-activated immunotherapies, receiving $52 million upfront, extending cash runway to 2026. Xilio Therapeutics, Inc., a clinical-stage ...
ABBV-RGX-314 in Diabetic Retinopathy (DR), Suprachoroidal Delivery AbbVie and REGENXBIO will plan a Phase 3 clinical program. The clinical program will utilize the in-office SCS Microinjector ...
are expected in 2026 AbbVie and REGENXBIO will plan the Phase 3 clinical program of investigational ABBV-RGX-314 in diabetic retinopathy (DR) ABBV-RGX-314 in Wet Age-Related Macular Degeneration ...
Pivotal data evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet age-related macular degeneration (wet AMD) are expected in 2026 AbbVie and REGENXBIO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback